MSKCC State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025

MSKCC State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025

 Include: 11 videos + 12 pdfs, size: 6.4 GB

Target Audience: general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers

Information:

This one-day symposium will provide a state-of-the-art update in benign hematology, with a particular focus on emerging therapeutic strategies. The program will feature in-depth presentations by expert faculty, with dedicated time for interactive discussion and Q&A.

Now in its 10th year, the 2025 program will focus on:

• Complex management scenarios in hemostasis and thrombosis, including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)
• Advances in management of hemolytic anemias, with a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders
• Hematologic complications related to cellular therapies and immunotherapies
• Novel treatment approaches, including factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use

The target audience for this symposium includes general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders. Please note that this symposium will be offered exclusively in person; a virtual attendance option will not be available.

Following the symposium, registrants will receive access to an online syllabus featuring select PDF slides from faculty presentations and recorded session videos.

1. Discuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics
2. Analyze current data and discuss emerging FXI inhibitors
3. Describe anticomplement therapies
4. Recognize the challenges in diagnosis and management of hematologic complications of immunotherapy

Topics:

Sunday, October 26, 2025